疗效的基线生物标志物和与bempegaldesleukin加nivolumabb相关的治疗时免疫特征变化

相关实验视频

Updated: Jun 20, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

Helen Gogas1, Shruthi Ravimohan2, Antara Datta2

  • 1National and Kapodistrian University of Athens, Athens, Greece. helgogas@gmail.com.

NPJ precision oncology
|July 18, 2024
PubMed
概括

在黑色素瘤中,bempegaldesleukin (BEMPEG) 和nivolumab (NIVO) 的组合没有显示任何额外的益处. 生物标志物分析显示,BEMPEG+NIVO增加了免疫细胞,也增加了调节性T细胞,这可能解释了临床疗效的缺乏.

更多相关视频

Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504